Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
9G2 Stock Chart & Stats
S$0.07
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.07
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume159.90K
Average Volume (3M)247.96K
Market Cap
S$59.11M
Enterprise ValueS$134.93M
Total Cash (Recent Filing)S$3.85M
Total Debt (Recent Filing)S$88.57M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,231,494,600
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthNearly doubling revenue in 2025 signals scalable demand and improving market traction for the company's services. Sustained top-line expansion can support investment in capacity, spread fixed costs, and create a runway for operating leverage if cost control continues.
Very High Gross MarginA sustained ~92% gross margin indicates structural pricing power or low direct costs, providing a wide gross-profit buffer. If maintained, this margin gives the company substantial room to absorb overhead and move toward operating profitability as volumes scale.
Material Improvement In Free Cash FlowA ~91% year-over-year improvement in free cash flow shows progress toward cash generation and reduced funding strain. While still negative, the trend lowers near-term financing needs if sustained, improving the prospects for long-term financial sustainability.
Bears Say
Deep, Persistent Net LossesA net margin near -167% means the business is consuming far more capital than it generates. Persistent, large losses erode shareholder equity and make the company's viability heavily dependent on either rapid margin recovery or continued external funding over the medium term.
Chronic Operating Cash BurnRepeated negative operating cash flow indicates the core operations are not self-financing, raising reliance on external financing or asset sales. Structural cash burn increases dilution and refinancing risk, limiting the firm's ability to invest or stabilize until operations turn cash-positive.
Elevated And Rising LeverageLeverage climbing back to ~1.05 after prior higher levels signals ongoing dependence on debt financing, reducing balance-sheet flexibility. Elevated leverage raises interest and refinancing risk, constraining strategic options while the company works to convert high gross margins into net profitability.
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$59.11M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 208 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on Feb 13, 2026. The company reported -S$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.009.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,231,494,600 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
-47.62%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.